NYSE - Delayed Quote USD

Abbott Laboratories (ABT)

134.80
+1.45
+(1.09%)
At close: May 16 at 4:00:02 PM EDT
134.01
-0.79
(-0.59%)
After hours: May 16 at 7:55:46 PM EDT

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Robert B. Ford Chairman of the Board, President & CEO 4.98M 9.81M 1974
Mr. Philip P. Boudreau CFO & Executive VP of Finance 2.18M -- 1973
Mr. Hubert L. Allen J.D. Executive VP, General Counsel & Secretary 2.55M 11.03M 1966
Mr. Daniel Gesua Sive Salvadori Executive VP and Group President of Established Pharmaceuticals & Nutritional Products 1.89M -- 1979
Ms. Lisa D. Earnhardt Executive VP & Group President of Medical Devices 2.26M -- 1970
Ms. Sabina Ewing Senior VP of Business & Technology Services and Chief Information Officer -- -- 1974
Mr. Michael Comilla Vice President of Investor Relations. -- -- --
Erica L. Battaglia VP and Chief Ethics & Compliance Officer -- -- --
Ms. Mary K. Moreland Executive Vice President of Human Resources -- -- 1966
Ms. Melissa Brotz Senior Vice President of Global Marketing & External Affairs -- -- --

Abbott Laboratories

100 Abbott Park Road
Abbott Park
North Chicago, IL 60064-6400
United States
224 667 6100 https://www.abbott.com
Sector: 
Healthcare
Industry: 
Medical Devices
Full Time Employees: 
114,000

Description

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company provides pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Corporate Governance

Abbott Laboratories’s ISS Governance QualityScore as of May 1, 2025 is 7. The pillar scores are Audit: 9; Board: 7; Shareholder Rights: 2; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

July 16, 2025 at 12:30 PM UTC - July 21, 2025 at 12:30 PM UTC

Abbott Laboratories Earnings Date

Recent Events

May 15, 2025 at 12:00 AM UTC

Dividend Date

May 1, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

April 30, 2025 at 12:00 AM UTC

10-Q: Periodic Financial Reports

April 28, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

April 16, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

April 15, 2025 at 12:00 AM UTC

Ex-Dividend Date

March 14, 2025 at 12:00 AM UTC

DEFA14A: Proxy Statements

February 21, 2025 at 12:00 AM UTC

10-K: Periodic Financial Reports

January 22, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

November 15, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

Related Tickers